We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation (ML20981)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00874419
First Posted: April 2, 2009
Last Update Posted: September 25, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Sun Yat-sen University
Shanghai Chest Hospital
RenJi Hospital
Guangdong Provincial People's Hospital
Peking Union Medical College Hospital
Information provided by (Responsible Party):
Caicun Zhou, Tongji University